Wren Therapeutics is advancing a unique, predictive chemical kinetics platform to discover small-molecule therapeutics for protein misfolding diseases. The company is progressing lead programs targeting amyloid-beta and alpha-synuclein, and reported a first clinical candidate for amyloid-beta in Q1 2021. Its pipeline has been expanded to include IAPP (diabetes), tau (Alzheimer’s and other tauopathies), and TDP-43 (motor neurone disease), and discovery work in oncology has commenced. Wren says its platform was industrialised over the past four years, building on more than a decade of prior academic research. Management and governance have been strengthened with board appointments (Andrew C. von Eschenbach and Owen Hughes) and senior hires including Alleyn Plowright as Head of Translational Science. Financially, the company has raised approximately £33 million to date, and the new financing is intended to accelerate its two lead programs toward the clinic and support its collaboration with Eisai. Wren Therapeutics is a spin‑out from the University of Cambridge and Lund University focused on drug discovery and development for protein misfolding diseases. The company advances a predictive, quantitatively driven platform built on concepts from the physical sciences and the chemical kinetics of protein misfolding. Wren is developing a broad pipeline of small‑molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases. The company is based at the University of Cambridge in the Chemistry of Health Centre and plans to open a satellite office in Boston, Massachusetts in the near term. Wren was formally founded in 2016 and has reported significant external interest across many important drug discovery targets. Financially, the company has completed an £18 million Series A financing led by The Baupost Group.

Total raised

$40M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2021